2009 Press Releases

Receive E-mail AlertsEmail Alerts
Sign up to receive e-mail alerts whenever MannKind has a news release. Just enter your e-mail address and click submit.
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
11/02/09CORRECTING and REPLACING MannKind Corporation Reports Third Quarter Financial Results
- Conference Call Today at 5:00 p.m. EST - VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 2, 2009-- Eighth graph, last sentence of release should read: A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (888) 393-9645 or (203) 369-3721 and entering conference number 7091682 (sted A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 393-9645 or (203) 369-3721 and entering c... 
Printer Friendly Version
11/02/09MannKind to Present at Upcoming Conferences
VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 2, 2009-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. Imperial Capital’s 3rd Annual Global Opportunities Conference on Thursday, November 5, 2009 at 2:10 PM (EST) at the New York Palace Hotel in New York, New York ... 
Printer Friendly Version
11/02/09MannKind Corporation Reports Third Quarter Financial Results
- Conference Call Today at 5:00 p.m. EST - VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 2, 2009-- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the third quarter ended September 30, 2009. For the third quarter of 2009, total operating expenses were $42.8 million, compared to $69.1 million for the third quarter of 2008. Research and development (R&D) expenses were $30.5 million for the third quarter ... 
Printer Friendly Version
10/29/09Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies
New Data on MKC1106-MT and MKC1106-PP Presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting WASHINGTON--(BUSINESS WIRE)--Oct. 29, 2009-- Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid ma... 
Printer Friendly Version
10/26/09MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 2, 2009
VALENCIA, Calif.--(BUSINESS WIRE)--Oct. 26, 2009-- MannKind Corporation (Nasdaq:MNKD) will release its 2009 third quarter financial results on Monday, November 2, 2009. Management of the Company will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM EST on November 2, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chie... 
Printer Friendly Version
10/02/09AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment
Long-Term Study in Adults with Type 2 Diabetes Presented at the 45th Annual Meeting of the European Association for the Study of Diabetes VIENNA--(BUSINESS WIRE)--Oct. 2, 2009-- AFRESA® (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, ... 
Printer Friendly Version
09/29/09MannKind to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Sep. 29, 2009-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Tuesday, October 6, 2009 at 9:00 AM (EDT) at the New York Palace Hotel in New York, New York. Interested parties can access a link to the live webcast of the ... 
Printer Friendly Version
09/29/09Study Shows AFRESA(R) Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients
Latest Data on Ultra Rapid Acting Insulin Presented at the 45th Annual Meeting of the European Association for the Study of Diabetes VIENNA--(BUSINESS WIRE)--Sep. 29, 2009-- AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the Europe... 
Printer Friendly Version
09/03/09MannKind to Present at Upcoming Conferences
VALENCIA, Calif., Sep 03, 2009 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. Rodman & Renshaw Annual Global Investment Conference on Thursday, September 10, 2009 at 11:40 AM (EDT) at the New York Palace Hotel in New York Morgan Stanley Global Healthcare Conference on... 
Printer Friendly Version
08/10/09MannKind Announces Completion of Common Stock Offering
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 10, 2009-- MannKind Corporation (Nasdaq: MNKD) today announced the completion of a public offering of 8,360,000 shares of its common stock, including 960,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. MannKind’s chairman, chief executive officer and principal stockholder, Alfred E. Mann, purchased 1,000,000 of these shares from the underwr... 
Printer Friendly Version
08/06/09MannKind to Present at the 29th Annual Canaccord Adams Global Growth Conference
VALENCIA, Calif., Aug 06, 2009 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 29th Annual Canaccord Adams Global Growth Conference on Wednesday, August 12, 2009 at 1:00 PM (EDT) at the InterContinental Hotel in Boston, Massachusetts. Interested parties can access a link to the live webcast of the presentati... 
Printer Friendly Version
08/05/09MannKind Announces Pricing of Public Offering of Common Stock
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 5, 2009-- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of the public offering of 7,400,000 shares of its common stock. MannKind’s chairman, chief executive officer and principal stockholder, Alfred E. Mann, is purchasing 1,000,000 of these shares from the underwriters. All of the shares are being offered by MannKind. MannKind expects the offering to close on or about August 10, 2009, su... 
Printer Friendly Version
08/03/09MannKind Corporation Reports Second Quarter Financial Results
Conference Call Today at 5:00 p.m. EDT VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 3, 2009-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2009. For the second quarter of 2009, total operating expenses were $53.4 million, compared to $80.9 million for the second quarter of 2008. Research and development (R&D) expenses were $39.8 million for the second quarter of 2009 compared to $67.6 ... 
Printer Friendly Version
07/27/09MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2009
VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 27, 2009-- MannKind Corporation (Nasdaq: MNKD) will release its 2009 second quarter financial results on Monday, August 3, 2009. Management of the Company will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM EDT on August 3, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chi... 
Printer Friendly Version
07/14/09MannKind Announces Positive New Market Survey Information Regarding AFRESA(R)
VALENCIA, Calif.--(BUSINESS WIRE)--Jul. 14, 2009-- MannKind Corporation (Nasdaq: MNKD) today released new information related to the market potential for AFRESA, MannKind’s ultra rapid-acting insulin. In a market survey conducted in May 2009 involving 101 endocrinologists and 102 primary care physicians (all based in the United States) and utilizing MannKind’s next generation inhaler, physicians expressed a preference for... 
Printer Friendly Version
06/22/09MannKind Closes Acquisition of Insulin Assets from Pfizer
VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 22, 2009-- MannKind Corporation (Nasdaq:MNKD) today announced that it has completed its acquisition from Pfizer Inc. (NYSE:PFE) of a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery pursuant to an insulin sale and purchase agreement. Upon the closing, MannKind and Pfizer also entered into an agreement pursuant to which MannKind agreed to maintain and store the rem... 
Printer Friendly Version
06/08/09MannKind Unveils Next-Generation Inhalation System
Designed to further enhance drug delivery and performance, increase ease of use for patients VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 8, 2009-- MannKind Corporation (Nasdaq:MNKD) announced today that it has begun clinical development of a next-generation inhalation system to optimize the delivery of drug powders based on the proprietary Technosphere® technology platform. The inhalation system is as small as a whistle and designed to be easy-to-use, discreet... 
Printer Friendly Version
06/06/09AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Ass... 
Printer Friendly Version
06/06/09Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
Latest data on ultra rapid acting insulin presented at the American Diabetes Association's 69th Scientific Sessions NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and r... 
Printer Friendly Version
06/03/09MannKind to Present at the Needham Life Sciences Conference
VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 3, 2009-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 10:00 AM (EDT) at The New York Palace Hotel in New York City. Interested parties can access a link to the live webcast of the presentation f... 
Printer Friendly Version
05/18/09FDA Accepts MannKind's Submission and Files NDA for AFRESA
VALENCIA, Calif.--(BUSINESS WIRE)--May. 18, 2009-- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed MannKind’s New Drug Application (NDA) for AFRESA®, an ultra rapid-acting insulin. MannKind is seeking FDA approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia. About AFRESA ... 
Printer Friendly Version
05/05/09MannKind to Present at the Canaccord Adams Diabetes and Obesity Conference
VALENCIA, Calif.--(BUSINESS WIRE)--May. 5, 2009-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Canaccord Adams Diabetes and Obesity Conference on Tuesday, May 12, 2009 at 8:20 AM (EDT) at the InterContinental Barclay Hotel in New York City. Interested parties can access a link to the live webcast of the present... 
Printer Friendly Version
05/04/09MannKind Corporation Reports First Quarter of 2009 Financial Results
- Conference Call to Begin Today at 4:00 PM EDT - VALENCIA, Calif.--(BUSINESS WIRE)--May. 4, 2009-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2009. For the first quarter of 2009, total operating expenses were $57.8 million, compared to $74.1 million for the first quarter of 2008. Research and development (R&D) expenses decreased by $15.6 million to $42.9 million for the first q... 
Printer Friendly Version
04/27/09MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
VALENCIA, Calif., April 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2009 first quarter financial results on Monday, May 4, 2009. Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 4:00 PM EDT on May 4, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corpora... 
Printer Friendly Version
03/16/09MannKind Submits NDA for AFRESA for Treatment of Diabetes
VALENCIA, Calif., March 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFRESA(R) (insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia. There are 23.6 million people in the United States, or 8% of t... 
Printer Friendly Version
03/09/09MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
VALENCIA, Calif., March 9 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into agreements with Pfizer Inc. (NYSE: PFE) to purchase Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery. The ... 
Printer Friendly Version
02/26/09MannKind Updates Status of NDA Submission for AFRESA
VALENCIA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today provided an update on the status of its new drug application ("NDA") for AFRESA(R), an ultra rapid-acting insulin that has completed Phase 3 clinical trials. As previously announced, our internal goal was to submit the NDA to the Food and Drug Administration ("FDA") by the end of February. Based on editorial decisions made during the final stages of preparing the dossier, we have decided to ... 
Printer Friendly Version
02/17/09MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results
VALENCIA, Calif., Feb 17, 2009 /PRNewswire via COMTEX/ -- - Conference Call to Begin Today at 4:00 PM ET - MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and year ended December 31, 2008. For the fourth quarter of 2008, total operating expenses were $81.8 million, compared to $79.1 million for the fourth quarter of 2007. Research and development (R&D) expenses increased by $2.0 million to $68.8 million for the fourth quarter of 2008 compared to th... 
Printer Friendly Version
02/11/09MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
VALENCIA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 fourth quarter financial results on Tuesday, February 17, 2009. Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 4:00 p.m. ET on Tuesday, February 17, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief O... 
Printer Friendly Version
02/02/09MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
VALENCIA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference on Monday, February 9, 2009 at 2:15 PM (EST) at the Hilton Waldorf Astoria in New York City. In addition to this presentation, the Company will host a breakfast meeting for invited in... 
Printer Friendly Version
01/13/09MannKind Reports Successful Completion of Device Bioequivalence Trial
VALENCIA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra rapid acting insulin that recently completed Phase 3 clinical trials. Study 138 - Bioequivalence of Clinical and Commercial Scale Inhalers Study 138 compared the bioequivalence of MannKind... 
Printer Friendly Version


Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet